文献速递冠心病

替格瑞洛与氯吡格雷在ST段抬高型心肌梗死溶栓治疗后的随机临床试验

Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2018-01-01

本研究为多中心随机开放标签、盲法终点评价试验,纳入3799例接受溶栓治疗的ST段抬高型心肌梗死患者(<75岁),比较替格瑞洛与氯吡格雷的短期出血安全性。

要点

  • 溶栓后延迟使用替格瑞洛在30天TIMI大出血方面不劣于氯吡格雷。
  • 替格瑞洛组轻微及极小出血发生率高于氯吡格雷组。
  • 两组致死性出血、颅内出血及缺血复合终点发生率相似。

核心结论

  • 在<75岁接受溶栓治疗的STEMI患者中,溶栓后延迟给予替格瑞洛在30天TIMI大出血方面不劣于氯吡格雷。

研究设计与样本

  • 多中心、随机、开放标签、盲法终点评价试验,纳入3799例<75岁接受溶栓治疗的STEMI患者,来自10国152个中心,2015年11月至2017年11月入组。
  • 预设非劣效性出血绝对界值为1.0%。
  • 患者随机接受替格瑞洛(180 mg负荷, thereafter 90 mg bid)或氯吡格雷(300-600 mg负荷, thereafter 75 mg qd);溶栓后中位11.4小时随机,90%预先使用氯吡格雷。

主要发现

  • 轻微及极小出血替格瑞洛组更常见。

临床怎么用

  • 对于<75岁接受溶栓治疗的STEMI患者,溶栓后延迟使用替格瑞洛可作为氯吡格雷的替代选择,需注意轻微出血风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The bleeding safety of ticagrelor in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy remains uncertain. OBJECTIVE: To evaluate the short-term safety of ticagrelor when compared with clopidogrel in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. DESIGN, SETTING AND PARTICIPANTS: We conducted a multicenter, randomized, open-label with blinded end point adjudication trial that enrolled 3799 patients (younger than 75 years) with ST-segment elevation myocardial infarction receiving fibrinolytic therapy in 152 sites from 10 countries from November 2015 through November 2017. The prespecified upper boundary for noninferiority for bleeding was an absolute margin of 1.0%. INTERVENTIONS: Patients were randomized to ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300-mg to 600-mg loading dose, 75 mg daily thereafter). Patients were randomized with a median of 11.4 hours after fibrinolysis, and 90% were pretreated with clopidogrel. MAIN OUTCOMES AND MEASURES: The primary outcome was thrombolysis in myocardial infarction (TIMI) major bleeding through 30 days. RESULTS: The mean (SD) age was 58.0 (9.5) years, 2928 of 3799 patients (77.1%) were men, and 2177 of 3799 patients (57.3%) were white. At 30 days, TIMI major bleeding had occurred in 14 of 1913 patients (0.73%) receiving ticagrelor and in 13 of 1886 patients (0.69%) receiving clopidogrel (absolute difference, 0.04%; 95% CI, -0.49% to 0.58%; P < .001 for noninferiority). Major bleeding defined by the Platelet Inhibition and Patient Outcomes criteria and by the Bleeding Academic Research Consortium types 3 to 5 bleeding occurred in 23 patients (1.20%) in the ticagrelor group and in 26 patients (1.38%) in the clopidogrel group (absolute difference, -0.18%; 95% CI, -0.89% to 0.54; P = .001 for noninferiority). The rates of fatal (0.16% vs 0.11%; P = .67) and intracranial bleeding (0.42% vs 0.37%; P = .82) were similar between the ticagrelor and clopidogrel groups, respectively. Minor and minimal bleeding were more common with ticagrelor than with clopidogrel. The composite of death from vascular causes, myocardial infarction, or stroke occurred in 76 patients (4.0%) treated with ticagrelor and in 82 patients (4.3%) receiving clopidogrel (hazard ratio, 0.91; 95% CI, 0.67-1.25; P = .57). CONCLUSIONS AND RELEVANCE: In patients younger than 75 years with ST-segment elevation myocardial infarction, delayed administration of ticagrelor after fibrinolytic therapy was noninferior to clopidogrel for TIMI major bleeding at 30 days. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02298088.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. JAMA Cardiol. 2018. PMID: 29525822. doi:10.1001/jamacardio.2018.0612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。